readthroughSign in
Nov 12, 2026Quarterly update

ProQR reports Q3 2026 results, fully enrolls AX-0811 cohorts 1 and 2

ProQR said it expects initial AX-0811 target engagement data in early January 2027 and ended the quarter with €103 million in cash, extending runway into mid-2028.

ProQR Therapeutics N.V. reported financial and operating results for the third quarter ended September 30, 2026, on November 12, 2026. The company said the Phase 1 study of AX-0811, its next-generation editing oligonucleotide targeting NTCP for cholestatic diseases including biliary atresia, has fully enrolled its first two cohorts.1 ProQR had dosed the first participant in the AX-0811 Phase 1 trial in September 2026, and the first two healthy-volunteer cohorts are now fully enrolled, with initial target engagement data expected in early January 2027.1

On the related AX-0810 program, ProQR plans to present the complete Phase 1 dataset, including Cohort 3 results and 12-week follow-up data, along with new AX-0811 preclinical data, in December 2026 at the "Nature Conferences RNA at the Bench and Bedside V" meeting, following target engagement data the company had reported in June 2026.

Looking to the first half of 2027, ProQR outlined several expected milestones: starting its investigator-initiated trial for pediatric biliary atresia, reporting initial AX-0422 patient data in MPS I Hurler syndrome, and moving AX-2911 into clinical testing for MASH. ProQR also said it continues preparing for an investigator-initiated trial in pediatric biliary atresia in China, with initial clinical data expected in the first half of 2027.1 A potentially registration-enabling Phase 2 program, subject to regulatory interactions, is expected to start in mid-2027, with first interim analysis data expected by mid-2028.1

On AI capabilities, ProQR appointed Chris Hart, PhD, as Chief Data and AI Officer in September 2026; Hart previously led Data Science and AI/ML for Genetic Medicines at Eli Lilly and Company.1 The company also said Thomas Wolf, PhD, co-founder and Chief Scientific Officer of Hugging Face, joined its Board as a strategic AI advisor.1

Financially, ProQR held approximately €103.0 million in cash and cash equivalents at September 30, 2026, compared to €92.4 million at December 31, 2025.1 The company said this cash position supports a runway into mid-2028.1 Net loss for the quarter was €12.4 million, or €0.09 per diluted share, compared with €11.0 million, or €0.10 per diluted share, in the same period of 2025.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.